These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25416789)

  • 1. TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models.
    Ohkubo S; Kodama Y; Muraoka H; Hitotsumachi H; Yoshimura C; Kitade M; Hashimoto A; Ito K; Gomori A; Takahashi K; Shibata Y; Kanoh A; Yonekura K
    Mol Cancer Ther; 2015 Jan; 14(1):14-22. PubMed ID: 25416789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazol-1-yl)-1 H-pyrazolo[3,4- b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor.
    Uno T; Kawai Y; Yamashita S; Oshiumi H; Yoshimura C; Mizutani T; Suzuki T; Chong KT; Shigeno K; Ohkubo M; Kodama Y; Muraoka H; Funabashi K; Takahashi K; Ohkubo S; Kitade M
    J Med Chem; 2019 Jan; 62(2):531-551. PubMed ID: 30525599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.
    Shimomura A; Yamamoto N; Kondo S; Fujiwara Y; Suzuki S; Yanagitani N; Horiike A; Kitazono S; Ohyanagi F; Doi T; Kuboki Y; Kawazoe A; Shitara K; Ohno I; Banerji U; Sundar R; Ohkubo S; Calleja EM; Nishio M
    Mol Cancer Ther; 2019 Mar; 18(3):531-540. PubMed ID: 30679388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAS-116 (pimitespib), a heat shock protein 90 inhibitor, shows efficacy in preclinical models of adult T-cell leukemia.
    Ikebe E; Shimosaki S; Hasegawa H; Iha H; Tsukamoto Y; Wang Y; Sasaki D; Imaizumi Y; Miyazaki Y; Yanagihara K; Hamaguchi I; Morishita K
    Cancer Sci; 2022 Feb; 113(2):684-696. PubMed ID: 34794206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation.
    Lee Y; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
    Mol Cancer Ther; 2017 Jan; 16(1):16-24. PubMed ID: 28062703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors.
    Zhou D; Liu Y; Ye J; Ying W; Ogawa LS; Inoue T; Tatsuta N; Wada Y; Koya K; Huang Q; Bates RC; Sonderfan AJ
    Toxicol Appl Pharmacol; 2013 Dec; 273(2):401-9. PubMed ID: 24090817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.
    Graham B; Curry J; Smyth T; Fazal L; Feltell R; Harada I; Coyle J; Williams B; Reule M; Angove H; Cross DM; Lyons J; Wallis NG; Thompson NT
    Cancer Sci; 2012 Mar; 103(3):522-7. PubMed ID: 22181674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo.
    Liu YM; Tu HJ; Wu CH; Lai MJ; Yu SC; Chao MW; Wu YW; Teng CM; Pan SL; Liou JP
    Eur J Med Chem; 2021 Jul; 219():113428. PubMed ID: 33934008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
    Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
    Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
    Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
    Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
    Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
    Eur J Med Chem; 2020 Mar; 190():112086. PubMed ID: 32058238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.
    Tillotson B; Slocum K; Coco J; Whitebread N; Thomas B; West KA; MacDougall J; Ge J; Ali JA; Palombella VJ; Normant E; Adams J; Fritz CC
    J Biol Chem; 2010 Dec; 285(51):39835-43. PubMed ID: 20940293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
    Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
    Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thermodynamic Dissection of Potency and Selectivity of Cytosolic Hsp90 Inhibitors.
    Yoshimura C; Nagatoishi S; Kuroda D; Kodama Y; Uno T; Kitade M; Chong-Takata K; Oshiumi H; Muraoka H; Yamashita S; Kawai Y; Ohkubo S; Tsumoto K
    J Med Chem; 2021 Mar; 64(5):2669-2677. PubMed ID: 33621080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.
    Suzuki R; Kikuchi S; Harada T; Mimura N; Minami J; Ohguchi H; Yoshida Y; Sagawa M; Gorgun G; Cirstea D; Cottini F; Jakubikova J; Tai YT; Chauhan D; Richardson PG; Munshi N; Ando K; Utsugi T; Hideshima T; Anderson KC
    PLoS One; 2015; 10(12):e0143847. PubMed ID: 26630652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.
    Courtin A; Smyth T; Hearn K; Saini HK; Thompson NT; Lyons JF; Wallis NG
    Br J Cancer; 2016 Oct; 115(9):1069-1077. PubMed ID: 27673365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.
    Garon EB; Finn RS; Hamidi H; Dering J; Pitts S; Kamranpour N; Desai AJ; Hosmer W; Ide S; Avsar E; Jensen MR; Quadt C; Liu M; Dubinett SM; Slamon DJ
    Mol Cancer Ther; 2013 Jun; 12(6):890-900. PubMed ID: 23493311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
    Bao R; Lai CJ; Wang DG; Qu H; Yin L; Zifcak B; Tao X; Wang J; Atoyan R; Samson M; Forrester J; Xu GX; DellaRocca S; Borek M; Zhai HX; Cai X; Qian C
    Mol Cancer Ther; 2009 Dec; 8(12):3296-306. PubMed ID: 19952121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
    Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
    Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
    Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
    Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.